News

Life Sciences

Alpine Immune Sciences Raises $25 Million in Private Placement of Stock + Warrants

Alpine Immune Sciences Raises $25 Million in Private Placement of Stock + Warrants

Edward Kim | Equities.com |

Company recently showed positive data in cancer and graft versus host disease.


CEL-SCI Regains Full Compliance with NYSE American's Continued Listing Requirements

Edward Kim | Equities.com |

Company awaits final Phase 3 data in head and neck cancer (Image: CEL-SCI)


Amneal Gets Approval for Generic Version of Exelon Patch for Dementia

Edward Kim | Equities.com |

First transdermal product for this fast growing generic manufacturer (Image: Amneal Pharmaceuticals).


8 Biotech IPOs Delayed by the Government Shutdown

Edward Kim | Equities.com |

The delays could cause companies to seek alternative financing and put development pipelines on hold.


AgeX Therapeutics Reports Publication of Data Supporting Type II Diabetes and Obesity Therapy

Edward Kim | Equities.com |

Data in peer-reviewed journal support AgeX's stem cell therapeutic approach to metabolic diseases.


Dyadic International — Microcap Play in Multibillion-Dollar Biosimilars Market

Edward Kim | Equities.com |

Presenting at Biotech Showcase, Wednesday, Jan. 9, at 9am PT


Axsome Shows Positive Phase 2 Data in Major Depressive Disorder

Edward Kim | Equities.com |

AXS-05's novel multimodal mechanism of action is different from all currently marketed antidepressants (Image: Axsome).


NeuBase Therapeutics to Reverse Merge into Ohr Pharmaceutical

Edward Kim | Equities.com |

NeuBase will capture Ohr's Nasdaq listing as it develops therapies for genetic diseases caused by mutant proteins.


Bristol-Myers Squibb to Buy Celgene for $74 Billion

Edward Kim | Equities.com |

CELG shareholders to receive one BMY share + $50 in cash + 1 contingent value right worth potentially $9 for each CELG share


Exicure Shows Positive Early Data in Topical Psoriasis Treatment

Edward Kim | Equities.com |

First demonstrated clinical benefit of company's proprietary spherical nucleic acid (SNA) platform (Image: Exicure)